{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '4.', 'SELECTION AND WITHDRAWAL OF PATIENTS', 'Prospective waivers (exceptions) from study inclusion and exclusion criteria to allow patients to', 'be enrolled are not granted by sponsor or Syneos Health (see Section 11.1.2).', '4.1.', 'Patient Inclusion Criteria', 'Patients may be enrolled in this study only if they meet all of the following criteria:', 'a.', 'Patient is 6 to 16 years of age, inclusive, at baseline.', 'b. Patient weighs at least 44 pounds (20kg) at baseline.', 'c. Patient meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth', 'Edition (DSM-VTM) diagnostic criteria for TS and, in the opinion of the investigator,', \"patient, and caregiver/adult, the patient's active tics are causing distress or\", 'impairment.', 'd. Patient has a TTS of 20 or higher on the YGTSS at screening and baseline.', 'e.', 'Patient is able to swallow study medication whole.', 'f. Patient and caregiver/adult are willing to adhere to the medication regimen and to', 'comply with all study procedures.', 'g. Patient is in good general health, as indicated by medical and psychiatric history as', 'well as physical and neurological examination.', \"h. In the investigator's opinion, the patient and caregiver/adult have the ability to\", 'understand the nature of the study and its procedures, and the patient is expected to', 'complete the study as designed.', 'i.', 'Patient and caregiver/adult provide written informed consent/assent, depending on the', \"child's age, as appropriate, according to local regulations.\", 'j.', 'Females who are postmenarchal or >12 years of age may be included only if they', 'have a negative \u00df-HCG test at baseline or are sterile. Definitions of sterile are given', 'in Appendix L.', 'k. Females who are postmenarchal or >12 years of age whose male partners are', 'potentially fertile (ie, no vasectomy) must use highly effective birth control methods', 'for the duration of the study (ie, starting at screening) and for 30 days or 5 half-lives,', 'whichever is longer after the last dose of IMP. Further details are included', 'in Appendix L.', '4.2.', 'Patient Exclusion Criteria', 'Patients will not be enrolled in this study if they meet any of the following criteria:', 'a. Patient has a neurologic disorder other than TS that could obscure the evaluation of', 'tics.', '66']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', \"b. The patient's predominant movement disorder is stereotypy (coordinated movements\", 'that repeat continually and identically) associated with autism spectrum disorder.', 'c. Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another', 'psychotic disorder.', 'd. Patient has clinically significant depression at screening or baseline.', 'Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose', 'for at least 6 weeks before screening.', 'e. Patient has a history of suicidal intent or related behaviors within 2 years of', 'screening:', '- previous intent to act on suicidal ideation with a specific plan, irrespective of', 'level of ambivalence, at the time of suicidal thought', '- previous suicidal preparatory acts or behavior', 'f.', 'Patient has a history of a previous actual, interrupted, or aborted suicide attempt.', 'g. Patient has a first-degree relative who has completed suicide.', 'h. Patient has clinically significant OCD at baseline that, in the opinion of the', 'investigator, is the primary cause of impairment.', 'i.', 'Patient has received CBIT for TS or CBT for OCD within 4 weeks of screening.', 'j.', 'Patient has received any of the following concomitant medications for ties within the', 'specified exclusionary windows of first dose:', '- within 3 months: Depot neuroleptics, botulinum toxin, or tetrabenazine', '-', 'within 4 weeks: cannabidiol oil and valbenazine', '- within 21 days: Reserpine', '- within 14 days: Neuroleptics (oral), typical and atypical antipsychotics', '(see Appendix A), metoclopramide, levodopa, and dopamine agonists', 'Note: Use of stimulant medications, including amphetamine, methylphenidate,', 'and lisdexamfetamine, is allowed if primary use is for the treatment of ADHD and', 'dosing has been stable for at least 2 weeks before screening and no changes to', 'dose or frequency are anticipated during the course of the study.', 'Note: Use of atomoxetine is allowed if the primary use is for the treatment of', 'ADHD and dosing has been stable for at least 4 weeks before screening and no', 'changes to dose or frequency are anticipated during the course of the study.', 'Note: Use of benzodiazepines is allowed if primary use is not for tics, and dosing', 'has been stable for at least 4 weeks before screening.', 'Note: Use of topiramate (up to 200 mg/day) is allowed if dosing has been stable', 'for at least 4 weeks before screening.', '- Note: Use of guanfacine or clonidine is allowed regardless of indication (ie, if', 'prescribed for tics or Tourette syndrome) if the dosing has been stable for at least', '67']\n\n###\n\n", "completion": "END"}